Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Analytical validation of a standardized scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicenter collaboration.

Leung SCY, Nielsen TO, Zabaglo LA, Arun I, Badve SS, Bane AL, Bartlett JMS, Borgquist S, Chang MC, Dodson A, Ehinger A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hugh JC, Kos Z, Laenkholm AV, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Sugie T, van der Vegt B, Viale G, Hayes DF, McShane LM, Dowsett M; International Ki67 in Breast Cancer Working Group of the Breast International Group North American Breast Cancer Group (BIG-NABCG).

Histopathology. 2019 Apr 24. doi: 10.1111/his.13880. [Epub ahead of print]

PMID:
31017314
2.

The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer.

Barry P, Vatsiou A, Spiteri I, Nichol D, Cresswell GD, Acar A, Trahearn N, Hrebien S, Garcia-Murillas I, Chkhaidze K, Ermini L, Huntingford IS, Cottom H, Zabaglo L, Koelble K, Khalique S, Rusby JE, Muscara F, Dowsett M, Maley CC, Natrajan R, Yuan Y, Schiavon G, Turner N, Sottoriva A.

Clin Cancer Res. 2018 Oct 1;24(19):4763-4770. doi: 10.1158/1078-0432.CCR-17-3374. Epub 2018 Jun 11.

3.

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.

Bianchini G, Kiermaier A, Bianchi GV, Im YH, Pienkowski T, Liu MC, Tseng LM, Dowsett M, Zabaglo L, Kirk S, Szado T, Eng-Wong J, Amler LC, Valagussa P, Gianni L.

Breast Cancer Res. 2017 Feb 9;19(1):16. doi: 10.1186/s13058-017-0806-9.

4.

High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium.

Abubakar M, Howat WJ, Daley F, Zabaglo L, McDuffus LA, Blows F, Coulson P, Raza Ali H, Benitez J, Milne R, Brenner H, Stegmaier C, Mannermaa A, Chang-Claude J, Rudolph A, Sinn P, Couch FJ, Tollenaar RA, Devilee P, Figueroa J, Sherman ME, Lissowska J, Hewitt S, Eccles D, Hooning MJ, Hollestelle A, Wm Martens J, Hm van Deurzen C, Investigators k, Bolla MK, Wang Q, Jones M, Schoemaker M, Broeks A, van Leeuwen FE, Van't Veer L, Swerdlow AJ, Orr N, Dowsett M, Easton D, Schmidt MK, Pharoah PD, Garcia-Closas M.

J Pathol Clin Res. 2016 Apr 6;2(3):138-53. doi: 10.1002/cjp2.42. eCollection 2016 Jul.

5.

Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration.

Leung SCY, Nielsen TO, Zabaglo L, Arun I, Badve SS, Bane AL, Bartlett JMS, Borgquist S, Chang MC, Dodson A, Enos RA, Fineberg S, Focke CM, Gao D, Gown AM, Grabau D, Gutierrez C, Hugh JC, Kos Z, Lænkholm AV, Lin MG, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Viale G, Hayes DF, McShane LM, Dowsett M.

NPJ Breast Cancer. 2016 May 18;2:16014. doi: 10.1038/npjbcancer.2016.14. eCollection 2016.

6.

Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.

López-Knowles E, Gao Q, Cheang MC, Morden J, Parker J, Martin LA, Pinhel I, McNeill F, Hills M, Detre S, Afentakis M, Zabaglo L, Dodson A, Skene A, Holcombe C, Robertson J, Smith I, Bliss JM, Dowsett M; POETIC trialists.

Breast Cancer Res. 2016 Apr 1;18(1):39. doi: 10.1186/s13058-016-0696-2.

7.

"Score the Core" Web-based pathologist training tool improves the accuracy of breast cancer IHC4 scoring.

Engelberg JA, Retallack H, Balassanian R, Dowsett M, Zabaglo L, Ram AA, Apple SK, Bishop JW, Borowsky AD, Carpenter PM, Chen YY, Datnow B, Elson S, Hasteh F, Lin F, Moatamed NA, Zhang Y, Cardiff RD.

Hum Pathol. 2015 Nov;46(11):1694-704. doi: 10.1016/j.humpath.2015.07.008. Epub 2015 Jul 29.

PMID:
26410019
8.

Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study.

Dodson A, Zabaglo L, Yeo B, Miller K, Smith I, Dowsett M.

J Clin Pathol. 2016 Feb;69(2):128-35. doi: 10.1136/jclinpath-2015-203212. Epub 2015 Aug 17.

PMID:
26281860
9.

Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study.

Yeo B, Zabaglo L, Hills M, Dodson A, Smith I, Dowsett M.

Br J Cancer. 2015 Jul 28;113(3):390-5. doi: 10.1038/bjc.2015.222. Epub 2015 Jul 16.

10.

An international study to increase concordance in Ki67 scoring.

Polley MY, Leung SC, Gao D, Mastropasqua MG, Zabaglo LA, Bartlett JM, McShane LM, Enos RA, Badve SS, Bane AL, Borgquist S, Fineberg S, Lin MG, Gown AM, Grabau D, Gutierrez C, Hugh JC, Moriya T, Ohi Y, Osborne CK, Penault-Llorca FM, Piper T, Porter PL, Sakatani T, Salgado R, Starczynski J, Lænkholm AV, Viale G, Dowsett M, Hayes DF, Nielsen TO.

Mod Pathol. 2015 Jun;28(6):778-86. doi: 10.1038/modpathol.2015.38. Epub 2015 Feb 20.

11.

An international Ki67 reproducibility study.

Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, Viale G, Zabaglo LA, Penault-Llorca F, Bartlett JM, Gown AM, Symmans WF, Piper T, Mehl E, Enos RA, Hayes DF, Dowsett M, Nielsen TO; International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group.

J Natl Cancer Inst. 2013 Dec 18;105(24):1897-906. doi: 10.1093/jnci/djt306. Epub 2013 Nov 7.

12.

Factors predicting late recurrence for estrogen receptor-positive breast cancer.

Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, Cuzick J.

J Natl Cancer Inst. 2013 Oct 2;105(19):1504-11. doi: 10.1093/jnci/djt244. Epub 2013 Sep 12.

13.

HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab.

Zabaglo L, Stoss O, Rüschoff J, Zielinski D, Salter J, Arfi M, Bradbury I, Dafni U, Piccart-Gebhart M, Procter M, Dowsett M; HERA Trial Study Team.

Ann Oncol. 2013 Nov;24(11):2761-6. doi: 10.1093/annonc/mdt275. Epub 2013 Jul 25.

PMID:
23894039
14.

Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.

Barton S, Zabaglo L, A'Hern R, Turner N, Ferguson T, O'Neill S, Hills M, Smith I, Dowsett M.

Br J Cancer. 2012 May 22;106(11):1760-5. doi: 10.1038/bjc.2012.166. Epub 2012 Apr 24.

15.

Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.

Lundgren K, Brown M, Pineda S, Cuzick J, Salter J, Zabaglo L, Howell A, Dowsett M, Landberg G; TransATAC investigators.

Breast Cancer Res. 2012 Apr 4;14(2):R57.

16.

Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF.

J Clin Oncol. 2011 Nov 10;29(32):4273-8. doi: 10.1200/JCO.2010.31.2835. Epub 2011 Oct 11.

PMID:
21990413
17.

Predictive algorithms for adjuvant therapy: TransATAC.

Dowsett M, Salter J, Zabaglo L, Mallon E, Howell A, Buzdar AU, Forbes J, Pineda S, Cuzick J.

Steroids. 2011 Jul;76(8):777-80. doi: 10.1016/j.steroids.2011.02.032. Epub 2011 Apr 4.

PMID:
21470560
18.

Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.

Anderson H, Hills M, Zabaglo L, A'hern R, Leary AF, Haynes BP, Smith IE, Dowsett M.

Ann Oncol. 2011 Aug;22(8):1770-6. doi: 10.1093/annonc/mdq700. Epub 2011 Feb 1.

PMID:
21285137
19.

Comparative validation of the SP6 antibody to Ki67 in breast cancer.

Zabaglo L, Salter J, Anderson H, Quinn E, Hills M, Detre S, A'Hern R, Dowsett M.

J Clin Pathol. 2010 Sep;63(9):800-4. doi: 10.1136/jcp.2010.077578. Epub 2010 Jul 29.

PMID:
20671052
20.

Who would have thought a single Ki67 measurement would predict long-term outcome?

Dowsett M, A'Hern R, Salter J, Zabaglo L, Smith IE.

Breast Cancer Res. 2009;11 Suppl 3:S15. doi: 10.1186/bcr2434. Epub 2009 Dec 18. No abstract available.

21.

Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques.

Ring AE, Zabaglo L, Ormerod MG, Smith IE, Dowsett M.

Br J Cancer. 2005 Mar 14;92(5):906-12.

22.
23.

Cell filtration-laser scanning cytometry for the characterisation of circulating breast cancer cells.

Zabaglo L, Ormerod MG, Parton M, Ring A, Smith IE, Dowsett M.

Cytometry A. 2003 Oct;55(2):102-8.

24.

Measurement of markers for breast cancer in a model system using laser scanning cytometry.

Zabaglo L, Ormerod MG, Dowsett M.

Cytometry. 2000 Nov 1;41(3):166-71.

PMID:
11042612
25.
26.

Argyrophilic nucleolar organizer regions, bromodeoxyuridine labelling index and DNA ploidy in squamous cell carcinoma of the uterine cervix.

Gasińska A, Zabagło L, Cichocka A, Pudełek J, Urbański K, Skołyszewski J.

Folia Histochem Cytobiol. 1996;34(2):95-101.

PMID:
8875218
27.

Micronucleus assay in three transplantable mouse tumors.

Gasińska A, Zabagło L, Cichocka A.

Neoplasma. 1995;42(5):243-8.

PMID:
8552203

Supplemental Content

Loading ...
Support Center